Ascendis Pharma A/S ASND Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$256.82 up $3.37, 1.33% at close Nov 6
Last close · Previous close $253.45
- Market cap
- $15.95BAt the Nov 6 close
- P/E ratio
- 20.36On last 12 months’ EPS
- Diluted EPS
- $12.61Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$256.82up $3.37, 1.33%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$253.45Nov 5
- Volume883.85KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume641.62KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $188.07 to $282.15; now $256.82
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
ASND beat the S&P 500 in 6 of 7 periods.
| Period | ASND and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ASND: up 13.6% S&P 500: down 5.6% | ASND beat the S&P 500 by 19.2 percentage points Beat |
| 3M | ASND: up 2.8% S&P 500: down 4.1% | ASND beat the S&P 500 by 6.9 percentage points Beat |
| YTD | ASND: up 20.4% S&P 500: up 8.7% | ASND beat the S&P 500 by 11.7 percentage points Beat |
| 1Y | ASND: up 28.9% S&P 500: up 10.9% | ASND beat the S&P 500 by 18.0 percentage points Beat |
| Long term | ||
| 3Y | ASND: up 172.0% S&P 500: up 75.0% +39.6% vs +20.5% a year | ASND beat the S&P 500 by 97.0 percentage points Beat |
| 5Y | ASND: up 59.8% S&P 500: up 67.8% +9.8% vs +10.9% a year | ASND trailed the S&P 500 by 8.0 percentage points Trailed |
| 10Y | ASND: up 1,234.1% S&P 500: up 313.1% +29.6% vs +15.2% a year | ASND beat the S&P 500 by 921.0 percentage points Beat |
$10,000 invested in ASND 10 years ago (Nov 4, 2016) would be worth about $133,413 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
ASND beat the S&P 500 in all 7 periods.
| Period | ASND and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ASND: up 13.6% S&P 500: down 5.6% | ASND beat the S&P 500 by 19.2 percentage points Beat |
| 3M | ASND: up 2.8% S&P 500: down 4.3% | ASND beat the S&P 500 by 7.1 percentage points Beat |
| YTD | ASND: up 20.4% S&P 500: up 7.8% | ASND beat the S&P 500 by 12.6 percentage points Beat |
| 1Y | ASND: up 28.9% S&P 500: up 9.7% | ASND beat the S&P 500 by 19.2 percentage points Beat |
| Long term | ||
| 3Y | ASND: up 172.0% S&P 500: up 68.8% +39.6% vs +19.1% a year | ASND beat the S&P 500 by 103.2 percentage points Beat |
| 5Y | ASND: up 59.8% S&P 500: up 56.9% +9.8% vs +9.4% a year | ASND beat the S&P 500 by 2.9 percentage points Beat |
| 10Y | ASND: up 1,234.1% S&P 500: up 252.6% +29.6% vs +13.4% a year | ASND beat the S&P 500 by 981.5 percentage points Beat |
$10,000 invested in ASND 10 years ago (Nov 4, 2016) would be worth about $133,413 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$277.18
Closing high on . Now 7.3% below that record.
Split-adjusted daily closes since Jan 28, 2015.
Stock splits
ASND hasn’t split since its price history begins in 2015.
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Jun 30, 2026). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
20.4×The Nov 6 close ÷ diluted EPS over the last 12 months ($12.61)
The range covers daily P/E ratios from Oct 28, 2021 to Nov 6, 2026, each based on the previous 12 months of earnings.
ASND trades at 20.4× its earnings over the last 12 months, above its 5-year median of 19.2×. In plain terms, buyers are paying about $20 for each $1 of profit from the past year. How to read P/E
Other valuation measures
- 13.2×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - 9.8×Book value as of Jun 30, 2026
Price relative to accounting equity (book value) per share on the Jun 30, 2026 balance sheet. Asset-light companies often trade far above book value.
P/B = Price ÷ Book value per sharePrice-to-book ratio - 41.7×Last 12 months’ EBITDA
Enterprise value divided by EBITDA over the last 12 months. It compares companies with different amounts of debt.
EV/EBITDA = Enterprise value ÷ EBITDA (last 12 months)EV/EBITDA explained - 2.40%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $15.55BAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Jun 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own ASND DCF in Excel. Value Ascendis Pharma A/S with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $1.21Bup 123.9%
- Net income
- $847.33M
- Diluted EPS
- $12.61
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $64.26M | −$110.22M | −$1.91 |
| Q4 FY24 (Dec 31, 2024) | $181.16M | −$40.07M | −$0.63 |
| Q1 FY25 (Mar 31, 2025) | $109.73M | −$102.85M | −$1.72 |
| Q2 FY25 (Jun 30, 2025) | $185.94M | −$45.71M | −$0.96 |
| Q3 FY25 (Sep 30, 2025) | $251.33M | −$71.75M | −$1.18 |
| Q4 FY25 (Dec 31, 2025) | $291.18M | −$39.48M | −$0.64 |
| Q1 FY26 (Mar 31, 2026) | $283.45M | $723.38M | $11.21 |
| Q2 FY26 (Jun 30, 2026) | $385.55M | $235.19M | $3.22 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $8.84M | −$435.88M | −$7.95 |
| FY22 (Dec 31, 2022) | $54.44M | −$620.42M | −$11.06 |
| FY23 (Dec 31, 2023) | $296.35M | −$534.94M | −$9.50 |
| FY24 (Dec 31, 2024) | $378.79M | −$393.84M | −$6.80 |
| FY25 (Dec 31, 2025) | $847.21M | −$268.28M | −$4.42 |
Margins
- Gross 91.3%
- Operating 25.1%
- Net 69.9%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- $383.51MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$400.10MLast 12 months
- Capital spending$16.59MLast 12 months
- 31.7%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $10.64MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paidNot reportedLast 12 months
Balance sheet
- $957.66MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$511.45MAs of Jun 30, 2026
- Net cash$446.21MAs of Jun 30, 2026
- 2.99As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.31As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 7 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✓Net income was positive: passed
- ✓Operating cash flow was positive: passed
- ✓Return on assets improved: passed
- ✗Operating cash flow exceeded net income: not passed
- ✓Long-term debt fell relative to assets: passed
- ✓Current ratio improved: passed
- ✗Share count didn’t rise: not passed
- ✓Gross margin improved: passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- 188.6%Last 12 months
Over the last 12 months, Ascendis Pharma A/S’s net income was 188.6% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return. ROE can run this high when equity is small, for example after years of large share buybacks.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - 43.5%Last 12 months
Over the last 12 months, Ascendis Pharma A/S’s net income was 43.5% of its total assets (averaged over the last four quarter-ends): what the business earned on everything it owns.
ROA = Net income (last 12 months) ÷ Average total assets
About Ascendis Pharma A/S
Ascendis Pharma is applying its innovative TransCon technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by its core values of Patients, Science, and Passion, Ascendis uses its TransCon technologies to create new and potentially best-in-class therapies. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Europe and the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Denmark
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
ASND news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
ASND stock FAQ
What is ASND stock’s price today?
Ascendis Pharma A/S (ASND) traded at $256.82 at the close on , up $3.37 (1.33%) from the previous close of $253.45. Over the past 52 weeks it has traded between $188.07 and $282.15.
If you invested $1,000 in ASND 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in ASND on would be worth about $13,341 at the close on , a total return of +1,234.1%. The same $1,000 would be worth $1,598 if invested five years ago and $1,289 if invested one year ago. Past performance doesn’t predict future returns.
What is Ascendis Pharma A/S’s market cap?
Ascendis Pharma A/S’s market capitalization is about $16.0 billion. That’s Tiingo’s daily market cap for , at that day’s closing price of $256.82 (how market cap works). Ascendis Pharma A/S reported 62.11M shares outstanding at the end of its latest quarter ().
What is ASND’s P/E ratio?
ASND trades at 20.4 times its diluted earnings over the four quarters to ($12.61 per share), at the close. Over the past five years its P/E has ranged from 16.4 to 28.6, with a median of 19.2. (How the P/E ratio works.)
How much revenue does Ascendis Pharma A/S make?
Ascendis Pharma A/S reported $1.2 billion of revenue over the four quarters to , up 123.9% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $385.6 million, up 107.4% from a year earlier.
Is Ascendis Pharma A/S profitable?
Yes. Ascendis Pharma A/S earned $847.3 million of net income over the four quarters to , a net margin of 69.9%, and its operating margin was 25.1% (what margins tell you).
What are ASND’s earnings per share?
ASND’s diluted earnings per share were $12.61 over the four quarters to , compared with −$5.22 in the twelve months before. The latest quarter (Q2 FY26) brought $3.22 per share, against −$0.96 a year earlier (how EPS works).
Does ASND pay a dividend?
Ascendis Pharma A/S hasn’t paid a dividend in the last twelve months.
What is ASND’s 52-week high and low?
Over the past 52 weeks ASND has traded as low as $188.07 and as high as $282.15. At $256.82 at the close on , it is 9.0% below that high and 36.6% above the low.
What is ASND’s all-time high?
ASND’s highest closing price was $277.18 on , adjusted for stock splits. At $256.82 at the close on , it is 7.3% below that record.
Has ASND stock ever split?
No. ASND hasn’t split since its price history begins in 2015.
How has ASND stock performed?
Including dividends and measured to the close on , ASND has returned +20.4% so far this year and +28.9% over the past year, and +59.8% over five years (+9.8% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Ascendis Pharma A/S in?
Ascendis Pharma A/S is in the Healthcare sector and the Biotechnology industry, and is headquartered in Denmark.
What exchange does ASND trade on?
Ascendis Pharma A/S trades on the Nasdaq under the ticker symbol ASND. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.